<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Onco Targets Ther</journal-id><journal-id journal-id-type="iso-abbrev">Onco Targets Ther</journal-id><journal-id journal-id-type="publisher-id">OncoTargets and Therapy</journal-id><journal-title-group><journal-title>OncoTargets and therapy</journal-title></journal-title-group><issn pub-type="epub">1178-6930</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5328300</article-id><article-id pub-id-type="doi">10.2147/OTT.S131014</article-id><article-id pub-id-type="publisher-id">ott-10-1149</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Association between TP53 gene Arg72Pro polymorphism and Wilms’ tumor risk in a Chinese population </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fu</surname><given-names>Wen</given-names></name><xref ref-type="aff" rid="af1-ott-10-1149">1</xref><xref ref-type="aff" rid="af2-ott-10-1149">2</xref><xref ref-type="author-notes" rid="fn1-ott-10-1149">*</xref></contrib><contrib contrib-type="author"><name><surname>Zhuo</surname><given-names>Zhen-Jian</given-names></name><xref ref-type="aff" rid="af3-ott-10-1149">3</xref><xref ref-type="author-notes" rid="fn1-ott-10-1149">*</xref></contrib><contrib contrib-type="author"><name><surname>Jia</surname><given-names>Wei</given-names></name><xref ref-type="aff" rid="af1-ott-10-1149">1</xref><xref ref-type="aff" rid="af2-ott-10-1149">2</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Jinhong</given-names></name><xref ref-type="aff" rid="af4-ott-10-1149">4</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Shi-Bo</given-names></name><xref ref-type="aff" rid="af1-ott-10-1149">1</xref><xref ref-type="aff" rid="af2-ott-10-1149">2</xref></contrib><contrib contrib-type="author"><name><surname>Lin</surname><given-names>Ze-Feng</given-names></name><xref ref-type="aff" rid="af1-ott-10-1149">1</xref><xref ref-type="aff" rid="af2-ott-10-1149">2</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Feng-Hua</given-names></name><xref ref-type="aff" rid="af1-ott-10-1149">1</xref><xref ref-type="aff" rid="af2-ott-10-1149">2</xref></contrib><contrib contrib-type="author"><name><surname>Xia</surname><given-names>Huimin</given-names></name><xref ref-type="aff" rid="af1-ott-10-1149">1</xref><xref ref-type="aff" rid="af2-ott-10-1149">2</xref></contrib><contrib contrib-type="author"><name><surname>He</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="af1-ott-10-1149">1</xref><xref ref-type="aff" rid="af2-ott-10-1149">2</xref><xref ref-type="corresp" rid="c2-ott-10-1149"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Guo-Chang</given-names></name><xref ref-type="aff" rid="af1-ott-10-1149">1</xref><xref ref-type="aff" rid="af2-ott-10-1149">2</xref><xref ref-type="corresp" rid="c1-ott-10-1149"/></contrib></contrib-group><aff id="af1-ott-10-1149"><label>1</label>Department of Pediatric Urology, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, Guangdong</aff><aff id="af2-ott-10-1149"><label>2</label>Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, Guangzhou, Guangdong</aff><aff id="af3-ott-10-1149"><label>3</label>Faculty of Medicine, School of Chinese Medicine, The Chinese University of Hong Kong, Hong Kong</aff><aff id="af4-ott-10-1149"><label>4</label>Molecular Epidemiology Laboratory, Department of Laboratory Medicine, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, People’s Republic of China</aff><author-notes><corresp id="c1-ott-10-1149">Correspondence: Guo-Chang Liu, Department of Pediatric Urology, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou 510623, Guangdong, People’s Republic of China, Email <email>starbless2003@126.com</email></corresp><corresp id="c2-ott-10-1149">Jing He, Department of Pediatric Surgery, Guangzhou Institute of Pediatrics, Guangzhou Women and Children’s Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou 510623, Guangdong, People’s Republic of China, Email <email>hejing198374@gmail.com</email></corresp><fn id="fn1-ott-10-1149"><label>*</label><p><text><SENT sid="1" pm="."><plain>These authors contributed equally to this work </plain></SENT>
</text></p></fn></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>23</day><month>2</month><year>2017</year></pub-date><volume>10</volume><fpage>1149</fpage><lpage>1154</lpage><permissions><copyright-statement>© 2017 Fu et al. This work is published and licensed by Dove Medical Press Limited</copyright-statement><copyright-year>2017</copyright-year><license><license-p>The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.</license-p></license></permissions><abstract><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Wilms’ tumor is one of the most prevalent pediatric malignancies, ranking fourth in childhood cancer worldwide. TP53 is a critical tumor suppressor gene, which encodes a 53 kDa protein, p53. </plain></SENT>
<SENT sid="3" pm="."><plain>The p53 functions to protect against cancer by regulating cell cycle and apoptosis and maintaining DNA integrity. TP53 gene is highly polymorphic. </plain></SENT>
<SENT sid="4" pm="."><plain>Several TP53 gene polymorphisms have been considered to be associated with cancer risk. </plain></SENT>
<SENT sid="5" pm="."><plain>Of them, a nonsynonymous polymorphism, Arg72Pro (rs1042522 C&gt;G), has been most extensively studied for the association with cancer risk; however, few studies have investigated its effect on Wilms’ tumor. </plain></SENT>
<SENT sid="6" pm="."><plain>Because of the central role of p53 in cell cycle control, the TP53 gene Arg72Pro polymorphism is also a good potential candidate predisposition locus for this pediatric cancer. </plain></SENT>
<SENT sid="7" pm="."><plain>We genotyped this polymorphism in 145 patients and 531 cancer-free controls recruited from Chinese children by Taqman methodology. </plain></SENT>
<SENT sid="8" pm="."><plain>Overall, our result suggested a lack of association between the TP53 gene Arg72Pro polymorphism and Wilms’ tumor. </plain></SENT>
<SENT sid="9" pm="."><plain>In the stratified analysis, we found that carriers of CG/GG genotypes had a significantly increased Wilms’ tumor risk in children not older than 18 months (adjusted odds ratio =2.04, 95% confidence interval =1.003–4.13, P=0.049) compared with CC genotype carriers. </plain></SENT>
<SENT sid="10" pm="."><plain>Our study indicated that the TP53 gene Arg72Pro polymorphism may have a weak, age-related effect on Wilms’ tumor risk in Chinese children. </plain></SENT>
<SENT sid="11" pm="."><plain>These findings need further validations in other populations with larger sample size. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group><title>Keywords</title><kwd><italic>TP53</italic></kwd><kwd>polymorphism</kwd><kwd>Wilms’ tumor</kwd><kwd>susceptibility</kwd></kwd-group></SecTag></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro"><title><text><SENT sid="12" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>Wilms’ tumor, also known as nephroblastoma, is the fourth most frequently diagnosed childhood cancer worldwide. </plain></SENT>
<SENT sid="14" pm="."><plain>It constitutes ~6% of all cancers detected among children younger than 15 years. </plain></SENT>
<SENT sid="15" pm="."><plain>The incidence rate of Wilms’ tumor varies geographically. </plain></SENT>
<SENT sid="16" pm="."><plain>The occurrence rate of Wilms’ tumor is ~1/8,000 children, with 400–650 new cases annually, in the USA1,2 and ~1/10,000 children in Western populations.3 Wilms’ tumor is also one of the most common renal tumors in children in China but less prevalent than that in Western countries, with an incidence rate of ~3.3 per million.4 Up to 2% of Wilms’ tumor cases are familial, with a known causal genetic lesion.5 No more than 5% of cases can be attributed to known causes, and the genetic basis underlying most Wilms’ tumors remains largely unknown.6,7 </plain></SENT>
</text></p><p><text><SENT sid="17" pm="."><plain>The human TP53 gene, encoding a 53 kDa protein (p53), is located on chromosome 17p13.1. TP53 gene is one of the most commonly mutated genes in human cancers.8 The TP53 gene is a tumor suppressor gene, playing an important role in the maintenance of DNA integrity, cell cycle control, and apoptosis.9–11 According to dbSNP database (<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/SNP">http://www.ncbi.nlm.nih.gov/projects/SNP</ext-link>), at least 1,462 single-nucleotide polymorphisms (SNPs) have been identified in the TP53 gene so far, supporting its highly polymorphic nature. </plain></SENT>
<SENT sid="18" pm="."><plain>Among them, the most commonly reported SNP is a non-synonymous Arg72Pro (rs1042522 C.G) polymorphism. </plain></SENT>
<SENT sid="19" pm="."><plain>This polymorphism is located in the exon 4 of the TP53 gene and can lead to the replacement of arginine (Arg) with proline (Pro) at codon 72. </plain></SENT>
<SENT sid="20" pm="."><plain>This polymorphism is able to alter the primary structures as well as biochemical functions of the p53 protein.12–14 It has been reported that the Arg72 form of p53 is more effective in inducing apoptosis and protecting cells from malignant transformation than the Pro72 variant.12,15 Numerous studies have been carried out to investigate the association between this polymorphism and cancer susceptibility.16–20 However, very few studies have investigated its association with Wilms’ tumor susceptibility and clinical outcomes until now.21,22 In light of the important tumor-suppressing role of TP53 gene, we investigated the association between the TP53 gene Arg72Pro polymorphism and Wilms’ tumor susceptibility in the current hospital-based case–control study with 145 cases and 531 cancer-free controls. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="methods|subjects"><title><text><SENT sid="21" pm="."><plain>Subjects and methods </plain></SENT>
</text></title><sec sec-type="subjects"><title><text><SENT sid="22" pm="."><plain>Subjects </plain></SENT>
</text></title><p><text><SENT sid="23" pm="."><plain>This study consisted of 145 newly diagnosed and histopathologically confirmed Wilms’ tumor patients from the Department of Pediatric Urology, Guangzhou Women and Children’s Medical Center.23 Patients were enrolled between March 2001 and June 2016. </plain></SENT>
<SENT sid="24" pm="."><plain>Controls were chosen from children who visited for routine physical examination, as we described previously.24–29 A total of 531 ethnicity-, age-, and gender-matched cancer-free controls were included in the study. </plain></SENT>
<SENT sid="25" pm="."><plain>Written informed consent was obtained from all subjects or their legal guardians in accordance with the principles of the Declaration of Helsinki. </plain></SENT>
<SENT sid="26" pm="."><plain>This study was approved by the Institutional Review Board of Guangzhou Women and Children’s Medical Center. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="27" pm="."><plain>DNA extraction and genotyping of TP53 gene Arg72Pro polymorphism </plain></SENT>
</text></title><p><text><SENT sid="28" pm="."><plain>Total genomic DNA was mainly isolated from the peripheral blood leukocytes using the TIANamp Blood DNA Kit (TianGen Biotech Co., Ltd., Beijing, China) as described previously.26 The TP53 gene Arg72Pro polymorphism was genotyped using the TaqMan real-time PCR method.26,30 Genotyping was performed blindly to the status of the case or control. </plain></SENT>
<SENT sid="29" pm="."><plain>Moreover, 10% of the samples were randomly selected to perform repeated assays, and the results were 100% concordant. </plain></SENT>
</text></p></sec><sec sec-type="methods"><title><text><SENT sid="30" pm="."><plain>Statistical analysis </plain></SENT>
</text></title><p><text><SENT sid="31" pm="."><plain>χ2 test was adopted to compare demographic characteristics and the frequency distributions of genotypes between cases and controls. </plain></SENT>
<SENT sid="32" pm="."><plain>Deviation from Hardy–Weinberg equilibrium (HWE) was tested using the χ2 goodness-of-fit test for the control subjects. </plain></SENT>
<SENT sid="33" pm="."><plain>Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to assess the association between the TP53 gene Arg72Pro polymorphism and Wilms’ tumor susceptibility. </plain></SENT>
<SENT sid="34" pm="."><plain>Adjusted ORs and corresponding 95% CIs adjusting for age and gender were calculated by unconditional multiple logistic regression model. </plain></SENT>
<SENT sid="35" pm="."><plain>Stratified analyses were performed by age, gender, and clinical stages. </plain></SENT>
<SENT sid="36" pm="."><plain>All the statistical tests were two sided, and P-values &lt;0.05 were considered as statistically significant. </plain></SENT>
<SENT sid="37" pm="."><plain>Statistical analysis was performed using the SAS software (Version 9.4; SAS Institute, Cary, NC, USA). </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results"><title><text><SENT sid="38" pm="."><plain>Results </plain></SENT>
</text></title><sec sec-type="intro"><title><text><SENT sid="39" pm="."><plain>Subject characteristics </plain></SENT>
</text></title><p><text><SENT sid="40" pm="."><plain>Epidemiological characteristics of Wilms’ tumor patients and cancer-free controls are listed in Table S1. </plain></SENT>
<SENT sid="41" pm="."><plain>The mean age was 26.17 months (±21.48, range =1–132 months) for Wilms’ tumor patients and 29.73 months (±24.86, range =0.07–156 months) for controls. </plain></SENT>
<SENT sid="42" pm="."><plain>No significant differences were observed between the patients and controls in the distribution of age (P=0.725) and gender (P=0.956). </plain></SENT>
<SENT sid="43" pm="."><plain>According to the classification of childhood renal tumors defined by NWTS-5 criteria,31 4 (2.76%), 49 (33.79%), 50 (34.48%), and 33 (22.76%) patients had clinical stages I, II, III, and IV Wilms’ tumor, respectively. </plain></SENT>
<SENT sid="44" pm="."><plain>Unfortunately, tumor specimens were not available for nine (6.21%) patients. </plain></SENT>
</text></p></sec><sec><title><text><SENT sid="45" pm="."><plain>Association between TP53 gene Arg72Pro polymorphism and Wilms’ tumor risk </plain></SENT>
</text></title><p><text><SENT sid="46" pm="."><plain>The genotype frequencies of the TP53 gene Arg72Pro polymorphism in the Wilms’ tumor patients and controls are listed in Table 1. </plain></SENT>
<SENT sid="47" pm="."><plain>Genotype analysis for the TP53 gene Arg72Pro polymorphism revealed that there was no significant deviation from the HWE in the control group (P=0.440). </plain></SENT>
<SENT sid="48" pm="."><plain>We did not observe any significant association between the TP53 gene Arg72Pro polymorphism and Wilms’ tumor susceptibility (CG vs CC: adjusted OR =1.48, 95% CI =0.95–2.32, P=0.086; GG vs CC: adjusted OR =1.02, 95% CI =0.58–1.78, P=0.948; CG/GG vs CC: adjusted OR =1.33, 95% CI =0.87–2.04, P=0.191; and GG vs CC/CG: adjusted OR =0.78, 95% CI =0.49–1.25, P=0.307). </plain></SENT>
</text></p><p><text><SENT sid="49" pm="."><plain>We further explored the association between the TP53 gene Arg72Pro polymorphism and Wilms’ tumor susceptibility in the stratified analysis by age, gender, and clinical stages (Table 2). </plain></SENT>
<SENT sid="50" pm="."><plain>Significant association was observed in children aged 18 months or younger (OR =2.06, 95% CI =1.02–4.18, P=0.045, and adjusted OR =2.04, 95% CI =1.003–4.13, P=0.049). </plain></SENT>
<SENT sid="51" pm="."><plain>It was suggested that younger children (≤18 months old) with CG/GG genotypes were at significantly higher risk of Wilms’ tumor than those with CC genotypes. </plain></SENT>
<SENT sid="52" pm="."><plain>However, no significant associations were observed in other stratified analyses. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion"><title><text><SENT sid="53" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="54" pm="."><plain>In the current hospital-based case–control study with 145 cases and 531 unrelated cancer-free controls, we did not observe any significant association between the TP53 gene Arg72Pro polymorphism and Wilms’ tumor susceptibility among Southern Chinese children. </plain></SENT>
<SENT sid="55" pm="."><plain>Interestingly, we found that the carriers of CG/GG genotypes, if 18 months old or younger, had a significantly increased Wilms’ tumor risk compared with counterparts carrying wild-type CC genotypes. </plain></SENT>
</text></p><p><text><SENT sid="56" pm="."><plain>The TP53 gene (gene ID: 7157) is also known as P53 gene. </plain></SENT>
<SENT sid="57" pm="."><plain>It encodes a p53 tumor suppressor protein that contains DNA binding, transcriptional activation, and oligomerization domains.32,33 The p53 protein can regulate the expression of target genes in response to diverse cellular stresses, thereby inducing DNA repair, cell cycle arrest, metabolism changes, apoptosis, and cellular senescence accordingly.9–11,34 The p53 protein has been recognized as the guardian of human cells against cancer.9,35 However, this gene is highly mutated, and mutations in the TP53 gene have been implicated in the various types of cancer in human beings.36 Apart from the predisposition to mutations, TP53 is also highly polymorphic. </plain></SENT>
<SENT sid="58" pm="."><plain>A great number of SNPs has been identified in the TP53 gene. </plain></SENT>
<SENT sid="59" pm="."><plain>Several TP53 gene SNPs have been shown to confer cancer susceptibility, such as the rs78378222 A&gt;C polymorphism discovered by whole-genome sequencing in 2011. </plain></SENT>
<SENT sid="60" pm="."><plain>We recently performed a meta-analysis to investigate the association between TP53 gene rs78378222 A&gt;C and overall cancer risk.37 Evidence from 34 studies including 36,599 cases and 91,272 controls confirmed that this polymorphism was significantly associated with an increased overall cancer risk.37 The TP53 gene Arg72Pro polymorphism is the most extensively investigated variant among the known TP53 gene susceptibility loci, which was first reported by Matlashewski et al.38 Intriguingly, the two alleles of this nonsynonymous polymorphism differ in the capacity of inducing target gene transcription, consequentially modifying cancer susceptibility differentially.13,39,40 </plain></SENT>
</text></p><p><text><SENT sid="61" pm="."><plain>As so far, numerous studies have been conducted to investigate the association between this polymorphism and cancer susceptibility.16–20 Klug et al16 carried out a meta-analysis by including a total of 49 studies with 7,946 cases and 7,888 controls. </plain></SENT>
<SENT sid="62" pm="."><plain>They found that the TP53 gene Arg72-Pro polymorphism was not associated with cervical cancer risk when the analyses were restricted to methodologically sound studies. </plain></SENT>
<SENT sid="63" pm="."><plain>Dahabreh et al17 did not find any significant association between TP53 gene Arg72Pro polymorphism and colorectal cancer with evidence from 23 studies including 6,514 cases and 9,334 controls. </plain></SENT>
<SENT sid="64" pm="."><plain>Xu et al18 combined 15 publications and found that the TP53 gene Arg72Pro polymorphism was associated with a significantly increased bladder cancer risk among Asians but not among Caucasians. </plain></SENT>
<SENT sid="65" pm="."><plain>Dahabreh et al19 carried out a meta-analysis involving breast cancer (68 studies), lung cancer (42), colorectal cancer (26), ovarian cancer (16), and endometrial cancer (8). </plain></SENT>
<SENT sid="66" pm="."><plain>They found that the association with the TP53 gene Arg72Pro polymorphism only existed among studies using tumor tissue as the source of genotyping material for cases (22 studies) but not among studies using other sources of genotyping material (eg, blood). </plain></SENT>
<SENT sid="67" pm="."><plain>However, it should be noted that the use of tumor tissue as the source of genotyping material for cases can lead to bias in the association studies. </plain></SENT>
<SENT sid="68" pm="."><plain>In the study by Tian et al20 with 14 investigations, including 2,506 cases and 4,386 controls, no association was observed between the TP53 gene Arg72Pro polymorphism and leukemia risk. </plain></SENT>
</text></p><p><text><SENT sid="69" pm="."><plain>However, there is lack of evidence of the association between the TP53 gene Arg72Pro polymorphism and Wilms’ tumor risk to date. </plain></SENT>
<SENT sid="70" pm="."><plain>Only one case–control study has been performed to examine the association of this polymorphism with Wilms’ tumor risk22 using controls from other studies. </plain></SENT>
<SENT sid="71" pm="."><plain>In the study with 46 cases and 300 controls, Andrade et al22 found that carriers of the rs1042522 C allele may associate with an increased Wilms’ tumor risk. </plain></SENT>
<SENT sid="72" pm="."><plain>In our present study, we failed to find any significant association between the TP53 gene Arg72Pro polymorphism and Wilms’ tumor risk, which was similar to most previous investigations in other types of cancer.16,17,20 Failure to find any significant association between the TP53 gene Arg72Pro polymorphism and Wilms’ tumor risk may be ascribed to the weak effect of low-penetrant SNPs, ethnicity difference, as well as the limited sample size in the current study. </plain></SENT>
<SENT sid="73" pm="."><plain>We found that the TP53 gene Arg72Pro polymorphism may contribute to a weak effect for Wilms’ tumor risk in Chinese children aged 18 months and younger, which may be ascribed to the fact that young children may be more genetic susceptible to Wilms’ tumor risk; besides, it may be a chance finding for the sample size, which is relatively small. </plain></SENT>
</text></p><p><text><SENT sid="74" pm="."><plain>Although this is the first investigation to assess the association between TP53 gene Arg72Pro polymorphism and Wilms’ tumor risk in Chinese children, our results should be interpreted with cautious for several limitations should be addressed. </plain></SENT>
<SENT sid="75" pm="."><plain>First, due to the low occurrence rate of Wilms’ tumor, only 145 cases were included in this study, which may have limited statistical power. </plain></SENT>
<SENT sid="76" pm="."><plain>Second, because of the nature of retrospective study design, we were only able to collect age, gender, ethnicity, and geographical factors for cases and controls. </plain></SENT>
<SENT sid="77" pm="."><plain>Other factors, such as dietary intake and parental environment exposures, were not available. </plain></SENT>
<SENT sid="78" pm="."><plain>Third, we just performed a case–control designed study to investigate the association between TP53 Arg72Pro polymorphism and Wilms’ tumor risk and we did not explore the potential mechanisms in cell lines for this polymorphism, which need to be investigated in future. </plain></SENT>
<SENT sid="79" pm="."><plain>Finally, we included only the most frequently investigated Arg72Pro polymorphism, and other TP53 gene polymorphisms (such as rs78378222 A.C) were not examined in this study. </plain></SENT>
</text></p></sec></SecTag><SecTag type="CONCL"><sec><title><text><SENT sid="80" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="81" pm="."><plain>This study indicated that the TP53 gene Arg72Pro polymorphism may contribute to a weak effect for Wilms’ tumor risk in Chinese children aged 18 months and younger. </plain></SENT>
<SENT sid="82" pm="."><plain>However, further prospective studies with larger sample size, different ethnicities, and more polymorphisms are required to confirm our findings. </plain></SENT>
</text></p></sec></SecTag><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="83" pm="."><plain>Supplementary material </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="SD1-ijn-8-2589"><SecTag type="TABLE"><table-wrap id="ts1-ott-10-1149" position="float"><label>Table S1</label><caption><p><text><SENT sid="84" pm="."><plain>Frequency distribution of selected variables in Wilms’ tumor patients and controls </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1"><text><SENT sid="85" pm="."><plain>Variables </plain></SENT>
</text></th><th colspan="2" valign="top" align="left" rowspan="1"><text><SENT sid="86" pm="."><plain>Cases (n=145)  </plain></SENT>
</text></th><th colspan="2" valign="top" align="left" rowspan="1"><text><SENT sid="87" pm="."><plain>Controls (n=531)  </plain></SENT>
</text></th><th rowspan="2" valign="top" align="left" colspan="1"><text><SENT sid="88" pm="."><plain>P-valuea </plain></SENT>
</text></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="89" pm="."><plain>N </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="90" pm="."><plain>% </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="91" pm="."><plain>N </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="92" pm="."><plain>% </plain></SENT>
</text></th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="93" pm="."><plain>Age range, months (mean ± SD) </plain></SENT>
</text></td><td colspan="2" valign="top" align="left" rowspan="1"><text><SENT sid="94" pm="."><plain>1–132 (26.17±21.48) </plain></SENT>
</text></td><td colspan="2" valign="top" align="left" rowspan="1"><text><SENT sid="95" pm="."><plain>0.07–156 (29.73±24.86) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="96" pm="."><plain>0.725 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="97" pm="."><plain> ≤18 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="98" pm="."><plain>66 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="99" pm="."><plain>45.52 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="100" pm="."><plain>66 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="101" pm="."><plain>45.52 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="102" pm="."><plain> &gt;18 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="103" pm="."><plain>79 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="104" pm="."><plain>54.48 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="105" pm="."><plain>79 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="106" pm="."><plain>54.48 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="107" pm="."><plain>Gender </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="108" pm="."><plain>0.956 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="109" pm="."><plain> Females </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="110" pm="."><plain>64 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="111" pm="."><plain>44.14 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="112" pm="."><plain>233 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="113" pm="."><plain>43.88 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="114" pm="."><plain> Males </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="115" pm="."><plain>81 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="116" pm="."><plain>55.86 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="117" pm="."><plain>298 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="118" pm="."><plain>56.12 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="119" pm="."><plain>Clinical stage </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="120" pm="."><plain> I </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="121" pm="."><plain>4 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="122" pm="."><plain>2.76 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="123" pm="."><plain> II </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="124" pm="."><plain>49 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="125" pm="."><plain>33.79 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="126" pm="."><plain> III </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="127" pm="."><plain>50 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="128" pm="."><plain>34.48 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="129" pm="."><plain> IV </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="130" pm="."><plain>33 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="131" pm="."><plain>22.76 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="132" pm="."><plain> NA </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="133" pm="."><plain>9 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="134" pm="."><plain>6.21 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p><text><SENT sid="135" pm="."><plain>Note: </plain></SENT>
</text></p></fn><fn id="tfn6-ott-10-1149"><label>a</label><p><text><SENT sid="136" pm="."><plain>Two-sided χ2 test for distributions between Wilms’ tumor patients and controls. </plain></SENT>
</text></p></fn><fn id="tfn7-ott-10-1149"><p><text><SENT sid="137" pm="."><plain>Abbreviations: NA, not available; SD, standard deviation. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack><title>Acknowledgments</title><p><text4fund><text><SENT sid="138" pm="."><plain>This study was supported by the grant of State Clinical Key Specialty Construction Project (Pediatric Surgery) 2013 (no GJLCZD1301) and the grant of Clinical Medicine Research and Transformation Center of Brain Injury in Premature Infant in Guangzhou (no 520101-2150092). </plain></SENT>
<SENT sid="139" pm="."><plain>We thank Hongjiao Chen, Yanlu Tong, and Hezhen Wang for their assistance in DNA extraction and Zhang Zhao and Jin-Hua Hu for their assistance in sample collection and medical histories information collection. </plain></SENT>
</text></text4fund></p></ack></SecTag><fn-group><fn fn-type="COI-statement"><p><text><SENT sid="140" pm="."><plain>Disclosure </plain></SENT>
</text></p><p><text><SENT sid="141" pm="."><plain>The authors report no conflicts of interest in this work. </plain></SENT>
</text></p></fn></fn-group><SecTag type="REF"><ref-list><title>References</title><ref id="b1-ott-10-1149"><text><SENT sid="142" pm="."><plain>1RiveraMNHaberDAWilms’ tumour: connecting tumorigenesis and organ development in the kidneyNat Rev Cancer20055969971216110318 </plain></SENT>
</text></ref><ref id="b2-ott-10-1149"><text><SENT sid="143" pm="."><plain>2ChuAHeckJERibeiroKBWilms’ tumour: a systematic review of risk factors and meta-analysisPaediatr Perinat Epidemiol201024544946920670226 </plain></SENT>
</text></ref><ref id="b3-ott-10-1149"><text><SENT sid="144" pm="."><plain>3StillerCAParkinDMInternational variations in the incidence of childhood renal tumoursBr J Cancer1990626102610302175212 </plain></SENT>
</text></ref><ref id="b4-ott-10-1149"><text><SENT sid="145" pm="."><plain>4BaoPPLiKWuCXRecent incidences and trends of childhood malignant solid tumors in Shanghai, 2002–2010Zhonghua Er Ke Za Zhi201351428829423927803 </plain></SENT>
</text></ref><ref id="b5-ott-10-1149"><text><SENT sid="146" pm="."><plain>5ScottRHStillerCAWalkerLRahmanNSyndromes and constitutional chromosomal abnormalities associated with Wilms tumourJ Med Genet200643970571516690728 </plain></SENT>
</text></ref><ref id="b6-ott-10-1149"><text><SENT sid="147" pm="."><plain>6ScottRHDouglasJBaskcombLConstitutional 11p15 abnormalities, including heritable imprinting center mutations, cause nonsyndromic Wilms tumorNat Genet200840111329133418836444 </plain></SENT>
</text></ref><ref id="b7-ott-10-1149"><text><SENT sid="148" pm="."><plain>7LittleSEHanksSPKing-UnderwoodLFrequency and heritability of WT1 mutations in nonsyndromic Wilms’ tumor patients: a UK Children’s Cancer Study Group StudyJ Clin Oncol200422204140414615483024 </plain></SENT>
</text></ref><ref id="b8-ott-10-1149"><text><SENT sid="149" pm="."><plain>8HarrisCCHollsteinMClinical implications of the p53 tumor-suppressor geneN Engl J Med199332918131813278413413 </plain></SENT>
</text></ref><ref id="b9-ott-10-1149"><text><SENT sid="150" pm="."><plain>9LevineAJp53, the cellular gatekeeper for growth and divisionCell19978833233319039259 </plain></SENT>
</text></ref><ref id="b10-ott-10-1149"><text><SENT sid="151" pm="."><plain>10SagerRTumor suppressor genes: the puzzle and the promiseScience19892464936140614122574499 </plain></SENT>
</text></ref><ref id="b11-ott-10-1149"><text><SENT sid="152" pm="."><plain>11XuHel-GewelyMRP53-responsive genes and the potential for cancer diagnostics and therapeutics developmentBiotechnol Annu Rev2001713116411686042 </plain></SENT>
</text></ref><ref id="b12-ott-10-1149"><text><SENT sid="153" pm="."><plain>12DumontPLeuJIDella PietraAC3rdGeorgeDLMurphyMThe codon 72 polymorphic variants of p53 have markedly different apoptotic potentialNat Genet200333335736512567188 </plain></SENT>
</text></ref><ref id="b13-ott-10-1149"><text><SENT sid="154" pm="."><plain>13ThomasMKalitaALabrecqueSPimDBanksLMatlashewskiGTwo polymorphic variants of wild-type p53 differ biochemically and biologicallyMol Cell Biol1999192109211009891044 </plain></SENT>
</text></ref><ref id="b14-ott-10-1149"><text><SENT sid="155" pm="."><plain>14SiddiqueMSabapathyKTrp53-dependent DNA-repair is affected by the codon 72 polymorphismOncogene200625253489350016462765 </plain></SENT>
</text></ref><ref id="b15-ott-10-1149"><text><SENT sid="156" pm="."><plain>15WhibleyCPharoahPDHollsteinMp53 polymorphisms: cancer implicationsNat Rev Cancer2009929510719165225 </plain></SENT>
</text></ref><ref id="b16-ott-10-1149"><text><SENT sid="157" pm="."><plain>16KlugSJRessingMKoenigJTP53 codon 72 polymorphism and cervical cancer: a pooled analysis of individual data from 49 studiesLancet Oncol200910877278419625214 </plain></SENT>
</text></ref><ref id="b17-ott-10-1149"><text><SENT sid="158" pm="."><plain>17DahabrehIJLinardouHBouzikaPVarvarigouVMurraySTP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysisCancer Epidemiol Biomarkers Prev20101971840184720615891 </plain></SENT>
</text></ref><ref id="b18-ott-10-1149"><text><SENT sid="159" pm="."><plain>18XuTXuZCZouQYuBHuangXEP53 Arg72Pro polymorphism and bladder cancer risk – meta-analysis evidence for a link in Asians but not CaucasiansAsian Pac J Cancer Prev20121352349235422901221 </plain></SENT>
</text></ref><ref id="b19-ott-10-1149"><text><SENT sid="160" pm="."><plain>19DahabrehIJSchmidCHLauJVarvarigouVMurraySTrikalinosTAGenotype misclassification in genetic association studies of the rs1042522 TP53 (Arg72Pro) polymorphism: a systematic review of studies of breast, lung, colorectal, ovarian, and endometrial cancerAm J Epidemiol2013177121317132523729685 </plain></SENT>
</text></ref><ref id="b20-ott-10-1149"><text><SENT sid="161" pm="."><plain>20TianXDaiSSunJJiangSJiangYAssociation between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studiesSci Rep201662409727053289 </plain></SENT>
</text></ref><ref id="b21-ott-10-1149"><text><SENT sid="162" pm="."><plain>21CostNGMituiMKhokharSWickiserJEBakerLARakhejaDTP53 codon 72 polymorphisms in favorable histology Wilms tumorsPediatr Blood Cancer201259232632822052810 </plain></SENT>
</text></ref><ref id="b22-ott-10-1149"><text><SENT sid="163" pm="."><plain>22AndradeRCCardosoLCFermanSEAssociation of TP53 polymorphisms on the risk of Wilms tumorPediatr Blood Cancer201461343644124038938 </plain></SENT>
</text></ref><ref id="b23-ott-10-1149"><text><SENT sid="164" pm="."><plain>23FuWZhuJXiongSWBARD1 gene polymorphisms confer nephroblastoma susceptibilityEBioMedicineEpub201713110.1016/j.ebiom.2017.01.038 </plain></SENT>
</text></ref><ref id="b24-ott-10-1149"><text><SENT sid="165" pm="."><plain>24HeJWangFZhuJAssociation of potentially functional variants in the XPG gene with neuroblastoma risk in a Chinese populationJ Cell Mol Med20162081481149027019310 </plain></SENT>
</text></ref><ref id="b25-ott-10-1149"><text><SENT sid="166" pm="."><plain>25HeJYangTZhangRPotentially functional polymorphisms in the LIN28B gene contribute to neuroblastoma susceptibility in Chinese childrenJ Cell Mol Med20162081534154127021521 </plain></SENT>
</text></ref><ref id="b26-ott-10-1149"><text><SENT sid="167" pm="."><plain>26HeJZhangRZouYEvaluation of GWAS-identified SNPs at 6p22 with neuroblastoma susceptibility in a Chinese populationTumour Biol20163721635163926307394 </plain></SENT>
</text></ref><ref id="b27-ott-10-1149"><text><SENT sid="168" pm="."><plain>27HeJZhongWZengJLMO1 gene polymorphisms contribute to decreased neuroblastoma susceptibility in a Southern Chinese populationOncotarget2016716227702277827009839 </plain></SENT>
</text></ref><ref id="b28-ott-10-1149"><text><SENT sid="169" pm="."><plain>28ZhangRZouYZhuJThe association between GWAS-identified BARD1 gene SNPs and neuroblastoma susceptibility in a Southern Chinese populationInt J Med Sci201613213313826941572 </plain></SENT>
</text></ref><ref id="b29-ott-10-1149"><text><SENT sid="170" pm="."><plain>29ZhengJZhangRZhuJLack of associations between XPC gene polymorphisms and neuroblastoma susceptibility in a Chinese populationBiomed Res Int20162016293204927847809 </plain></SENT>
</text></ref><ref id="b30-ott-10-1149"><text><SENT sid="171" pm="."><plain>30HeJQiuLXWangMYPolymorphisms in the XPG gene and risk of gastric cancer in Chinese populationsHum Genet201213171235124422371296 </plain></SENT>
</text></ref><ref id="b31-ott-10-1149"><text><SENT sid="172" pm="."><plain>31BeckwithJBNational Wilms Tumor Study: an update for pathologistsPediatr Dev Pathol199811798410463275 </plain></SENT>
</text></ref><ref id="b32-ott-10-1149"><text><SENT sid="173" pm="."><plain>32IsobeMEmanuelBSGivolDOrenMCroceCMLocalization of gene for human p53 tumour antigen to band 17p13Nature1986320605784853456488 </plain></SENT>
</text></ref><ref id="b33-ott-10-1149"><text><SENT sid="174" pm="."><plain>33FinlayCAHindsPWLevineAJThe p53 proto-oncogene can act as a suppressor of transformationCell1989577108310932525423 </plain></SENT>
</text></ref><ref id="b34-ott-10-1149"><text><SENT sid="175" pm="."><plain>34ScopinaroMJCasakSJPaediatric oncology in Argentina: medical and ethical issuesLancet Oncol20023211111711902522 </plain></SENT>
</text></ref><ref id="b35-ott-10-1149"><text><SENT sid="176" pm="."><plain>35PetitjeanAAchatzMIBorresen-DaleALHainautPOlivierMTP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomesOncogene200726152157216517401424 </plain></SENT>
</text></ref><ref id="b36-ott-10-1149"><text><SENT sid="177" pm="."><plain>36FrebourgTFriendSHCancer risks from germline p53 mutationsJ Clin Invest1992905163716411430194 </plain></SENT>
</text></ref><ref id="b37-ott-10-1149"><text><SENT sid="178" pm="."><plain>37WangYWuXSHeJMaTLeiWShenZYA novel TP53 variant (rs78378222 A &gt; C) in the polyadenylation signal is associated with increased cancer susceptibility: evidence from a meta-analysisOncotarget2016722328543286527147571 </plain></SENT>
</text></ref><ref id="b38-ott-10-1149"><text><SENT sid="179" pm="."><plain>38MatlashewskiGJTuckSPimDLambPSchneiderJCrawfordLVPrimary structure polymorphism at amino acid residue 72 of human p53Mol Cell Biol1987729619633547088 </plain></SENT>
</text></ref><ref id="b39-ott-10-1149"><text><SENT sid="180" pm="."><plain>39MarinMCJostCABrooksLAA common polymorphism acts as an intragenic modifier of mutant p53 behaviourNat Genet2000251475410802655 </plain></SENT>
</text></ref><ref id="b40-ott-10-1149"><text><SENT sid="181" pm="."><plain>40StoreyAThomasMKalitaARole of a p53 polymorphism in the development of human papillomavirus-associated cancerNature199839366822292349607760 </plain></SENT>
</text></ref></ref-list></SecTag></back><floats-group><SecTag type="TABLE"><table-wrap id="t1-ott-10-1149" position="float"><label>Table 1</label><caption><p><text><SENT sid="182" pm="."><plain>Genotype distributions of TP53 gene rs1042522 C&gt;G polymorphism and Wilms’ tumor risk </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="183" pm="."><plain>Genotype </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="184" pm="."><plain>Cases (N=144), n (%) </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="185" pm="."><plain>Controls (N=530), n (%) </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="186" pm="."><plain>P-valuea </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="187" pm="."><plain>Crude OR (95% CI) </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="188" pm="."><plain>P-value </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="189" pm="."><plain>Adjusted OR (95% CI)b </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="190" pm="."><plain>P-valueb </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="8" valign="top" align="left" rowspan="1"><text><SENT sid="191" pm="."><plain>rs1042522 (HWE =0.440) </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="192" pm="."><plain> CC </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="193" pm="."><plain>34 (23.61) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="194" pm="."><plain>155 (29.25) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="195" pm="."><plain>1.00 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="196" pm="."><plain>1.00 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="197" pm="."><plain> CG </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="198" pm="."><plain>83 (57.64) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="199" pm="."><plain>255 (48.11) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="200" pm="."><plain>1.48 (0.95–2.32) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="201" pm="."><plain>0.083 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="202" pm="."><plain>1.48 (0.95–2.32) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="203" pm="."><plain>0.086 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="204" pm="."><plain> GG </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="205" pm="."><plain>27 (18.75) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="206" pm="."><plain>120 (22.64) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="207" pm="."><plain>1.03 (0.59–1.79) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="208" pm="."><plain>0.929 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="209" pm="."><plain>1.02 (0.58–1.78) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="210" pm="."><plain>0.948 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="211" pm="."><plain> Additive </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="212" pm="."><plain>0.127 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="213" pm="."><plain>1.04 (0.80–1.35) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="214" pm="."><plain>0.792 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="215" pm="."><plain>1.03 (0.79–1.34) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="216" pm="."><plain>0.814 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="217" pm="."><plain> Dominant </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="218" pm="."><plain>110 (76.39) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="219" pm="."><plain>375 (70.75) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="220" pm="."><plain>0.176 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="221" pm="."><plain>1.34 (0.87–2.05) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="222" pm="."><plain>0.183 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="223" pm="."><plain>1.33 (0.87–2.04) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="224" pm="."><plain>0.191 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="225" pm="."><plain> Recessive </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="226" pm="."><plain>117 (81.25) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="227" pm="."><plain>410 (77.36) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="228" pm="."><plain>0.310 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="229" pm="."><plain>0.79 (0.50–1.26) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="230" pm="."><plain>0.317 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="231" pm="."><plain>0.78 (0.49–1.25) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="232" pm="."><plain>0.307 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn1-ott-10-1149"><label>a</label><p><italic>χ</italic><sup>2</sup> test for genotype distributions between Wilms’ tumor patients and controls.</p></fn><fn id="tfn2-ott-10-1149"><label>b</label><p>Adjusted for age and gender.</p></fn><fn id="tfn3-ott-10-1149"><p><bold>Abbreviations:</bold> CI, confidence interval; OR, odds ratio; HWE, Hardy–Weinberg equilibrium.</p></fn></table-wrap-foot></table-wrap></SecTag><SecTag type="TABLE"><table-wrap id="t2-ott-10-1149" position="float"><label>Table 2</label><caption><p><text><SENT sid="233" pm="."><plain>Stratification analysis for the association between TP53 gene rs1042522 C&gt;G polymorphism and Wilms’ tumor risk </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" valign="top" align="left" colspan="1"><text><SENT sid="234" pm="."><plain>Variables </plain></SENT>
</text></th><th colspan="2" valign="top" align="left" rowspan="1"><text><SENT sid="235" pm="."><plain>rs1042522 (cases/controls)  </plain></SENT>
</text></th><th rowspan="2" valign="top" align="left" colspan="1"><text><SENT sid="236" pm="."><plain>Crude OR (95% CI) </plain></SENT>
</text></th><th rowspan="2" valign="top" align="left" colspan="1"><text><SENT sid="237" pm="."><plain>P-value </plain></SENT>
</text></th><th rowspan="2" valign="top" align="left" colspan="1"><text><SENT sid="238" pm="."><plain>Adjusted ORa (95% CI) </plain></SENT>
</text></th><th rowspan="2" valign="top" align="left" colspan="1"><text><SENT sid="239" pm="."><plain>P-valuea </plain></SENT>
</text></th></tr><tr><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="240" pm="."><plain>CC </plain></SENT>
</text></th><th valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="241" pm="."><plain>CG/GG </plain></SENT>
</text></th></tr></thead><tbody><tr><td colspan="7" valign="top" align="left" rowspan="1"><text><SENT sid="242" pm="."><plain>Age, months </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="243" pm="."><plain> ≤18 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="244" pm="."><plain>11/68 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="245" pm="."><plain>55/165 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="246" pm="."><plain>2.06 (1.02–4.18) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="247" pm="."><plain>0.045 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="248" pm="."><plain>2.04 (1.003–4.13) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="249" pm="."><plain>0.049 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="250" pm="."><plain> &gt;18 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="251" pm="."><plain>23/87 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="252" pm="."><plain>55/210 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="253" pm="."><plain>0.99 (0.57–1.71) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="254" pm="."><plain>0.973 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="255" pm="."><plain>1.00 (0.58–1.73) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="256" pm="."><plain>0.993 </plain></SENT>
</text></td></tr><tr><td colspan="7" valign="top" align="left" rowspan="1"><text><SENT sid="257" pm="."><plain>Gender </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="258" pm="."><plain> Females </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="259" pm="."><plain>18/71 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="260" pm="."><plain>46/161 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="261" pm="."><plain>1.13 (0.61–2.08) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="262" pm="."><plain>0.702 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="263" pm="."><plain>1.12 (0.61–2.07) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="264" pm="."><plain>0.711 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="265" pm="."><plain> Males </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="266" pm="."><plain>16/84 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="267" pm="."><plain>64/214 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="268" pm="."><plain>1.57 (0.86–2.87) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="269" pm="."><plain>0.143 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="270" pm="."><plain>1.56 (0.85–2.86) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="271" pm="."><plain>0.150 </plain></SENT>
</text></td></tr><tr><td colspan="7" valign="top" align="left" rowspan="1"><text><SENT sid="272" pm="."><plain>Clinical stage </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="273" pm="."><plain> I + II </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="274" pm="."><plain>10/155 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="275" pm="."><plain>42/375 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="276" pm="."><plain>1.74 (0.85–3.55) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="277" pm="."><plain>0.130 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="278" pm="."><plain>1.77 (0.86–3.65) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="279" pm="."><plain>0.119 </plain></SENT>
</text></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="280" pm="."><plain> III + IV </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="281" pm="."><plain>22/155 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="282" pm="."><plain>61/375 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="283" pm="."><plain>1.15 (0.68–1.93) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="284" pm="."><plain>0.609 </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="285" pm="."><plain>1.14 (0.68–1.92) </plain></SENT>
</text></td><td valign="top" align="left" rowspan="1" colspan="1"><text><SENT sid="286" pm="."><plain>0.627 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn><p><bold>Notes:</bold></p></fn><fn id="tfn4-ott-10-1149"><label>a</label><p>Adjusted for age and gender. The results are presented in bold if the 95% CI excluded 1 or <italic>P</italic>&lt;0.05.</p></fn><fn id="tfn5-ott-10-1149"><p><bold>Abbreviations:</bold> CI, confidence interval; OR, odds ratio.</p></fn></table-wrap-foot></table-wrap></SecTag></floats-group></article>
